Merck’s MRK blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancer indications, is the company's biggest ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

PAH patients with cardiovascular disease risk had similar hospitalization and mortality rates as those without after a ...

Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ...

Seven cases of patent ductus arteriosus with pulmonary hypertension and reversal of the usual direction of flow are described. Breathing of a low oxygen mixture either initiated or increased the ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

The meta-analysis suggests that prophylactic indomethacin reduces the incidence of short-term morbidities such as later PDA (RR 0.29, CI 0.22 to 0.38), PDA ligation (RR 0.51, CI 0.33 to 0.71 ...

Pulmonary hypertension (PH) is now defined as mean pulmonary artery pressure >20 mm Hg according to the updated clinical classification from the 6th World Symposium of Pulmonary Hypertension (WSPH) ...

Transforming Pulmonary Arterial Hypertension Management: Bridging Clinical Practice, Innovative Therapies, and Economic Impact : Episode 7 Opinion Video June 19, 2025 ...

Paradigm Shift in PAH Management: Sotatercept vs. Prostacyclin Pathway Therapies The introduction of sotatercept is driving a significant paradigm shift in pulmonary arterial hypertension (PAH ...

Group 4: CTEPH (chronic thromboembolic pulmonary hypertension)—In some patients, pulmonary embolism, or blood clots, in the lung’s arteries can form scar-like tissue, blocking or narrowing the ...

If you are diagnosed with pulmonary hypertension (PH) or your doctor suspects PH, it is important for you to see a specialist. Pulmonary arterial hypertension (PAH) is a rare, progressive lung disease ...